Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

About this update from Ascendis Pharma A/s

[{"type":"image","alt":"Ascendis Pharma","displaySize":"","headline":null,"caption":"Ascendis Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/7afd0e29f0a4b40bcd5ff718a81f4afe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1tA.9j4XDPXN.zyLsOvv6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7afd0e29f0a4b40bcd5ff718a81f4afe","width":300,"height":100}},"lazy":false},{"type":"text","content":"- Rapidly transforming into a leading global biopharma company","length":62,"tagName":"p"},{"type":"text","content":"COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present this update on Monday, January 12, during the 44th Annual J.P. Morgan Healthcare Conference.","length":341,"tagName":"p"},{"type":"text","content":"“With our proven TransCon® technology platform, strong R&D capabilities, and a maturing commercial infrastructure and financial profile, Ascendis is rapidly transforming into a leading global biopharma company,” said Jan Mikkelsen, President and Chief Executive Officer at Ascendis Pharma. “Over the next year, this inflection will be driven by further global penetration and commercial expansion, a third potential TransCon product approval with blockbuster potential, and an advancing R&D pipeline of highly differentiated internal and external TransCon product candidates, all of which create the foundation for sustainable long-term growth.”","length":653,"tagName":"p"},{"type":"text","content":"Selected Key Updates and Milestones","length":35,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"TransCon PTH (palopegteriparatide, marketed as YORVIPATH®)","length":59,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"YORVIPATH fourth-quarter 2025 and full-year 2025 unaudited preliminary revenue expected to be ~€187 million and ~€477 million, respectively.","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"More than 5,300 unique U.S. patient enrollments, with nearly 2,400 unique prescribing healthcare providers at year end.","length":119,"tagName":"p"}]},{...

More updates from Ascendis Pharma A/s